K

Kiniksa Pharmaceuticals Ltd
D

KNSA

44.920
USD
-0.47
(-1.04%)
مغلق
حجم التداول
34,758
الربح لكل سهم
1
العائد الربحي
-
P/E
60
حجم السوق
3,437,969,135
أصول ذات صلة المقالات
المزيد

العنوان: Kiniksa Pharmaceuticals International plc

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.